Abstract
To determine the outcome of HIV infection in children in a resource-limited setting, a retrospective analysis of a series of 51 pediatric cases from the Serbian cohort of HIV infected patients was performed. Twenty seven patients died in the pre-HAART era, but mono/dual antiretroviral treatment had significantly (p=0.046) prolonged survival. Of the total of 24 HAART-treated patients, 10 had clinical AIDS before HAART initiation. The mean baseline CD4 cell count was 193.9 ± 170.0/mm3. After a mean follow-up of 72.6 ± 44 months, a favorable response was recorded in 62.5%, treatment failure (defined as non-achievement of undetectable viremia) in 20.8%, and a discrepant virological and immunological response (achievement of undetectable viremia but without a rise in CD4 cell counts adequate for age) in 16.7% patients. No patients died, and there were only three hospital admissions after commencing HAART. Five immune restoration inflammatory syndrome episodes were recorded, of which four were due to BCG-osis. Lipodystrophy and hyperlipidemia occurred in 18.2% and 26.3% patients, respectively. We conclude that even in suboptimal facilities, the prognosis of HIV disease among children on HAART may be rather good. The metabolic syndrome seems to emerge as an important issue among long-term surviving children on HAART.
Keywords: Pediatric HIV/AIDS, HAART, Prognosis
Current HIV Research
Title: The Prognosis of Pediatric AIDS in Serbia
Volume: 7 Issue: 3
Author(s): Djordje Jevtovic, Dubravka Salemovic, Jovan Ranin, Branko Brmbolic and Olgica Djurkovic-Djakovic
Affiliation:
Keywords: Pediatric HIV/AIDS, HAART, Prognosis
Abstract: To determine the outcome of HIV infection in children in a resource-limited setting, a retrospective analysis of a series of 51 pediatric cases from the Serbian cohort of HIV infected patients was performed. Twenty seven patients died in the pre-HAART era, but mono/dual antiretroviral treatment had significantly (p=0.046) prolonged survival. Of the total of 24 HAART-treated patients, 10 had clinical AIDS before HAART initiation. The mean baseline CD4 cell count was 193.9 ± 170.0/mm3. After a mean follow-up of 72.6 ± 44 months, a favorable response was recorded in 62.5%, treatment failure (defined as non-achievement of undetectable viremia) in 20.8%, and a discrepant virological and immunological response (achievement of undetectable viremia but without a rise in CD4 cell counts adequate for age) in 16.7% patients. No patients died, and there were only three hospital admissions after commencing HAART. Five immune restoration inflammatory syndrome episodes were recorded, of which four were due to BCG-osis. Lipodystrophy and hyperlipidemia occurred in 18.2% and 26.3% patients, respectively. We conclude that even in suboptimal facilities, the prognosis of HIV disease among children on HAART may be rather good. The metabolic syndrome seems to emerge as an important issue among long-term surviving children on HAART.
Export Options
About this article
Cite this article as:
Jevtovic Djordje, Salemovic Dubravka, Ranin Jovan, Brmbolic Branko and Djurkovic-Djakovic Olgica, The Prognosis of Pediatric AIDS in Serbia, Current HIV Research 2009; 7 (3) . https://dx.doi.org/10.2174/157016209788347912
DOI https://dx.doi.org/10.2174/157016209788347912 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Screening of Natural Lead Molecules Against Putative Molecular Targets of Drug-resistant Cryptococcus spp: An Insight from Computer-aided Molecular Design
Current Topics in Medicinal Chemistry Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: From Current Diagnostic Tools and Therapeutics for Alzheimer's Disease Towards Earlier Diagnostic Markers and Treatment Targets)
Current Alzheimer Research Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Applications of Animal Models of Infectious Arthritis in Drug Discovery:A focus on Alphaviral Disease
Current Drug Targets Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Copper, An Ancient Remedy Returning to Fight Microbial, Fungal and Viral Infections
Current Chemical Biology Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Retroperitoneal Cryptococcoma in a Case of Disseminated Cryptococcosis on Antifungal Maintenance Therapy
Current HIV Research Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Current Pharmaceutical Design Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research